|
|
Online Registration is Open
August 1st, 2018 |
|
Call for speakers!
August 1st, 2018 |
|
Welcome to the website of WCBI-2019 August 1st, 2018 |
|
|
|
Abstract Submission Start Day
August 1st, 2018 |
|
Earlybird Registration Start Day
August 1st, 2018 |
|
Earlybird Registration Deadline
Novermber 31st, 2018 |
|
Abstract Submission Deadline
Feburary
28th, 2019 |
|
Acceptance Notification Deadline
March 1st, 2019
|
|
|
|
|
|
|
|
|
On behalf of the organizing committee, we are proud to announce that World Congress of Biotherapy-2019 (WCBI-2019) will be held during March 23-24, 2019 in the beautiful city of Beijing, China. The conference's theme is “Innovation, Translation, and Promotion”.
The scientific program of WCBI-2019 will focus on 10 hot topics including cell immunotherapy, tumor immunotherapy, precision medicine and personalized therapy, next generation of gene sequencing technology, gene editing, big date of biomedicine, stem cell therapy, in vitro diagnosis (IVD), therapeutic antibody, and emerging vaccine. The keynote forum will be featured with Nobel Laureates, Academician, and Executives from leading biopharmaceuticals, and world-renowned scientists. 800+ professionals in the fields of biotherapy will participate in this event. It is aiming to provide an opportunity for professionals take part in and to influence future trends in one of the fastest growing biopharmaceutical industry sectors.
Beijing is an important world capital and global power city, Combining both modern and traditional architecture, Beijing is one of the oldest cities in the world, with a rich history dating back three millennia. On behalf of the organizing committee, we would like to invite you again to join us and witness the history and future of beautiful Beijing.
Best wishes,
Organizing Committee of WCBI-2019
|
|
Renowned Speakers |
|
|
|
Dr. Daiming Fan, Academician, Past President of Fourth Military Medical University; Director of State Key Laboratory of Cancer Biology, China |
Dr. Yongxiang Zhao, Professor & Vice President, Guangxi Medical University, China |
Dr. Joe Zhou. CEO of Genor Biopharma, VP and the R&D head of Walvax Bio Group, China |
|
|
|
Dr. Zhang Yi, Professor and Director, First Affiliated Hospital of Zhengzhou University |
Dr. Hairong Zheng, Professor and Vice Director of Shenzhen Institutes of Advanced Technology (SIAT), CAS, China |
Dr. Pengfei Zhou, Founder and CEO, YZY Biopharma Co.,Ltd., China |
|
|
|
Dr.Tao Hu, Professor and PhD Supervisor at the Chinese Academy of Sciences Institute of Process Engineering, China |
Dr. Wang Yu, Institute of Zoology, Chinese Academy of Sciences, Stem cells and Reproductive Biology
|
Dr. Yuelei Shen, President of Beijing Biocytogen Co.,Ltd, China |
|
|
|
Dr. Juhua Zhou, Professor, Ludong University School of Life Sciences, China |
Dr. Lu Wang, Professor, Peking University School of Medical Sciences, China |
Dr. Zhibo Gao, CEO, YuceBio LTD, China |
|
|
|
Dr. Liangpeng Ge, Director, Institute of Bioengineering, Chongqing Academy of Animal Sciences, China |
Dr. Qisen Guo, Professor, Shandong Cancer Hospital, China |
Dr. Jiapeng Zhou, Chief Medical Officer, MyGenostics Inc, China |
|
|
|
|
|